Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
about
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells.Glioblastoma Treatments: An Account of Recent Industrial DevelopmentsAkt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
P2860
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Efficacy of depatuxizumab mafo ...... i-center, international study.
@en
Efficacy of depatuxizumab mafo ...... i-center, international study.
@nl
type
label
Efficacy of depatuxizumab mafo ...... i-center, international study.
@en
Efficacy of depatuxizumab mafo ...... i-center, international study.
@nl
prefLabel
Efficacy of depatuxizumab mafo ...... i-center, international study.
@en
Efficacy of depatuxizumab mafo ...... i-center, international study.
@nl
P2093
P2860
P50
P1476
Efficacy of depatuxizumab mafo ...... i-center, international study.
@en
P2093
Andrew B Lassman
David A Reardon
David Maag
Earle Bain
Erica Gomez
Helen Wheeler
Ho-Jin Lee
John Simes
P2860
P2888
P304
P356
10.1007/S00280-017-3451-1
P577
2017-10-26T00:00:00Z